Stay updated with breaking news from Front Cell Dev. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In crafting a patient-centered regimen, the convergence of expertise from physicians and pharmacists, paired with the values and preferences of patients, becomes paramount.
With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.
There is no cause in the universe that is known to have such a capacity of foresight other than intelligent design.
Human reproduction is perhaps the quintessential example of teleology in biology.
The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.